Physicians' Academy for Cardiovascular Education

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Educational information

Educational objectives of this symposium were to:

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Faculty & Disclosures

Dr. Paul M Ridker, MD, MPH, is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston.


Supported by unrestricted educational grants from Amgen, Pfizer, and Sanofi-Regeneron

Also watch lecture: PCSK9, the short track road from discovery as drug target towards the clinic by Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France Also watch lecture: Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?, by John Kastelein, MD, AMC, Amsterdam, The Netherlands